Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line—IPO43

Fernanda Silva; Filipa Coelho; Ana Peixoto; Pedro Pinto; Carmo Martins; Ann Sophie Frombach; Vítor E. Santo; Catarina Brito; António Guimarães; Ana Félix

doi:10.1186/s12935-022-02600-3

Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line—IPO43

Fernanda Silva, Filipa Coelho, Ana Peixoto, Pedro Pinto, Carmo Martins, Ann Sophie Frombach, Vítor E. Santo, Catarina Brito, António Guimarães, Ana Félix

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

22 Downloads (Pure)

Abstract

BACKGROUND: Epithelial ovarian cancer (EOC) is an aggressive and lethal malignancy and novel EOC cell lines with detailed characterization are needed, to provide researchers with diverse helpful resources to study EOC biological processes and cancer experimental therapies.

METHODS: The IPO43 cell line was established from the ascitic fluid of a patient with a diagnosis of high-grade serous carcinoma (HGSC) of the ovary, previously treated with chemotherapy. Cell immortalization was achieved in 2D cell culture and growth obtained in 2D and 3D cell cultures. The characterization of immortalized cells was done by immunocytochemistry, flow cytometry, cell proliferation, chromosomal Comparative Genomic Hybridization (cCGH), STR profile and Next Generation Sequencing (NGS).

RESULTS: Characterization studies confirmed that IPO43 cell line is of EOC origin and maintains morphological and molecular features of the primary tumor. cCGH analysis showed a complex profile with gains and losses of specific DNA regions in both primary ascitic fluid and cell line IPO43. The cell line was successfully grown in a 3D system which allows its future application in more complex assays than those performed in 2D models. IPO43 cell line is resistant to standard drug treatment in vitro.

CONCLUSIONS: IPO43 is available for public research and we hope it can contribute to enrich the in vitro models addressing EOC heterogeneity, being useful to investigate EOC and to develop new therapeutic modalities.

Original language	English
Article number	175
Pages (from-to)	175
Journal	Cancer cell international
Volume	22
Issue number	1
DOIs	https://doi.org/10.1186/s12935-022-02600-3
Publication status	Published - 30 Apr 2022

Keywords

3D models
Cell lines
Chemoresistance
Ovarian cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12935-022-02600-3

s12935-022-02600-3Final published version, 6.89 MBLicence: CC BY

Cite this

@article{cc897fbe3ce140b1bdd3d23e7a7f00da,

title = "Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line—IPO43",

abstract = "BACKGROUND: Epithelial ovarian cancer (EOC) is an aggressive and lethal malignancy and novel EOC cell lines with detailed characterization are needed, to provide researchers with diverse helpful resources to study EOC biological processes and cancer experimental therapies.METHODS: The IPO43 cell line was established from the ascitic fluid of a patient with a diagnosis of high-grade serous carcinoma (HGSC) of the ovary, previously treated with chemotherapy. Cell immortalization was achieved in 2D cell culture and growth obtained in 2D and 3D cell cultures. The characterization of immortalized cells was done by immunocytochemistry, flow cytometry, cell proliferation, chromosomal Comparative Genomic Hybridization (cCGH), STR profile and Next Generation Sequencing (NGS).RESULTS: Characterization studies confirmed that IPO43 cell line is of EOC origin and maintains morphological and molecular features of the primary tumor. cCGH analysis showed a complex profile with gains and losses of specific DNA regions in both primary ascitic fluid and cell line IPO43. The cell line was successfully grown in a 3D system which allows its future application in more complex assays than those performed in 2D models. IPO43 cell line is resistant to standard drug treatment in vitro.CONCLUSIONS: IPO43 is available for public research and we hope it can contribute to enrich the in vitro models addressing EOC heterogeneity, being useful to investigate EOC and to develop new therapeutic modalities.",

keywords = "3D models, Cell lines, Chemoresistance, Ovarian cancer",

author = "Fernanda Silva and Filipa Coelho and Ana Peixoto and Pedro Pinto and Carmo Martins and Frombach, {Ann Sophie} and Santo, {V{\'i}tor E.} and Catarina Brito and Ant{\'o}nio Guimar{\~a}es and Ana F{\'e}lix",

note = "Funding Information: We acknowledge to Unidade Investiga{\c c}{\~a}o Patobiologia Molecular (UIPM) facilities and to Pathology Department of Instituto Portugu{\^e}s de Oncologia Francisco Gentil de Lisboa (IPOLFG). We acknowledge funding from the iNOVA4Health—UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Funda{\c c}{\~a}o para a Ci{\^e}ncia e Tecnologia / Minist{\'e}rio da Ci{\^e}ncia, Tecnologia e Ensino Superior (FCT/MCTES), through national funds”. Funding Information: The authors declare that the article was partially funded by iNOVA4Health—UIDB/04462/2020 and iNOVA4Health—UIDP/04462/2020. ",

year = "2022",

month = apr,

day = "30",

doi = "10.1186/s12935-022-02600-3",

language = "English",

volume = "22",

pages = "175",

journal = "Cancer cell international",

issn = "1475-2867",

publisher = "BioMed Central (BMC)",

number = "1",

}

TY - JOUR

T1 - Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line—IPO43

AU - Silva, Fernanda

AU - Coelho, Filipa

AU - Peixoto, Ana

AU - Pinto, Pedro

AU - Martins, Carmo

AU - Frombach, Ann Sophie

AU - Santo, Vítor E.

AU - Brito, Catarina

AU - Guimarães, António

AU - Félix, Ana

N1 - Funding Information: We acknowledge to Unidade Investigação Patobiologia Molecular (UIPM) facilities and to Pathology Department of Instituto Português de Oncologia Francisco Gentil de Lisboa (IPOLFG). We acknowledge funding from the iNOVA4Health—UIDB/04462/2020 and UIDP/04462/2020, a program financially supported by Fundação para a Ciência e Tecnologia / Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES), through national funds”. Funding Information: The authors declare that the article was partially funded by iNOVA4Health—UIDB/04462/2020 and iNOVA4Health—UIDP/04462/2020.

PY - 2022/4/30

Y1 - 2022/4/30

N2 - BACKGROUND: Epithelial ovarian cancer (EOC) is an aggressive and lethal malignancy and novel EOC cell lines with detailed characterization are needed, to provide researchers with diverse helpful resources to study EOC biological processes and cancer experimental therapies.METHODS: The IPO43 cell line was established from the ascitic fluid of a patient with a diagnosis of high-grade serous carcinoma (HGSC) of the ovary, previously treated with chemotherapy. Cell immortalization was achieved in 2D cell culture and growth obtained in 2D and 3D cell cultures. The characterization of immortalized cells was done by immunocytochemistry, flow cytometry, cell proliferation, chromosomal Comparative Genomic Hybridization (cCGH), STR profile and Next Generation Sequencing (NGS).RESULTS: Characterization studies confirmed that IPO43 cell line is of EOC origin and maintains morphological and molecular features of the primary tumor. cCGH analysis showed a complex profile with gains and losses of specific DNA regions in both primary ascitic fluid and cell line IPO43. The cell line was successfully grown in a 3D system which allows its future application in more complex assays than those performed in 2D models. IPO43 cell line is resistant to standard drug treatment in vitro.CONCLUSIONS: IPO43 is available for public research and we hope it can contribute to enrich the in vitro models addressing EOC heterogeneity, being useful to investigate EOC and to develop new therapeutic modalities.

AB - BACKGROUND: Epithelial ovarian cancer (EOC) is an aggressive and lethal malignancy and novel EOC cell lines with detailed characterization are needed, to provide researchers with diverse helpful resources to study EOC biological processes and cancer experimental therapies.METHODS: The IPO43 cell line was established from the ascitic fluid of a patient with a diagnosis of high-grade serous carcinoma (HGSC) of the ovary, previously treated with chemotherapy. Cell immortalization was achieved in 2D cell culture and growth obtained in 2D and 3D cell cultures. The characterization of immortalized cells was done by immunocytochemistry, flow cytometry, cell proliferation, chromosomal Comparative Genomic Hybridization (cCGH), STR profile and Next Generation Sequencing (NGS).RESULTS: Characterization studies confirmed that IPO43 cell line is of EOC origin and maintains morphological and molecular features of the primary tumor. cCGH analysis showed a complex profile with gains and losses of specific DNA regions in both primary ascitic fluid and cell line IPO43. The cell line was successfully grown in a 3D system which allows its future application in more complex assays than those performed in 2D models. IPO43 cell line is resistant to standard drug treatment in vitro.CONCLUSIONS: IPO43 is available for public research and we hope it can contribute to enrich the in vitro models addressing EOC heterogeneity, being useful to investigate EOC and to develop new therapeutic modalities.

KW - 3D models

KW - Cell lines

KW - Chemoresistance

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85129230430&partnerID=8YFLogxK

U2 - 10.1186/s12935-022-02600-3

DO - 10.1186/s12935-022-02600-3

M3 - Article

C2 - 35501869

SN - 1475-2867

VL - 22

SP - 175

JO - Cancer cell international

JF - Cancer cell international

IS - 1

M1 - 175

ER -

Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line—IPO43

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this